title: Evidence that sensitivity to cyclosporine is influenced by the HLA-DR phenotype of kidney graft recipients.
abstract: Clinical as well as experimental studies have shown a great interindividual variability in the immunosuppressive efficacy of CsA. Evaluating previous in vitro findings of a correlation between sensitivity of alloresponsiveness to CsA and the HLA-DR phenotype CsA levels were compared in kidney transplant recipients with and without rejections during the early posttransplant period and tested for a possible relationship to the HLA-DR phenotype of the recipient. In patients treated with CsA and prednisolone only, rejection frequency was significantly higher in HLA-DRw6 positive than in DRw6 negative graft recipients (77% vs. 53%, P = 0.045). In the DRw6 positive group incidence of rejection was independent of CsA blood levels, whereas in DRw6 negative patients frequency of rejection episodes decreased as a function of increasing CsA levels. Therefore the relative risk in developing graft rejection continuously increased in HLA-DRw6 positive patients. In HLA-DR2 positive graft recipients, however, a decrease in the relative risk could be observed with increasing CsA levels. Within patients with bioptically verified rejection episodes HLA-DR2 positive recipients had significantly lower CsA levels than DR2 negative patients (P = 0.01). In other HLA-DR phenotypes no association with CsA blood levels could be assessed. Also no statistically significant difference could be found in nonrejecting patients. These clinical findings demonstrate an association of sensitivity to immunosuppressive treatment and the HLA-DR phenotype of the graft recipient. Our results would indicate a very low CsA sensitivity of HLA-DRw6 positive graft recipients and thus might offer an explanation for previous findings about an increase in the incidence of rejection reported on those patients.
authors.affiliation: Second Department of Medicine, University of Vienna, Austria.
authors.forename: G J
authors.initials: GJ
authors.lastname: Zlabinger
authors.forename: S
authors.initials: S
authors.lastname: Kudlacek
authors.forename: E
authors.initials: E
authors.lastname: Pohanka
authors.forename: M
authors.initials: M
authors.lastname: Franz
authors.forename: G
authors.initials: G
authors.lastname: Hamilton
authors.forename: A
authors.initials: A
authors.lastname: Rosenmayr
authors.forename: J
authors.initials: J
authors.lastname: Kovarik
mesh_terms: D000328:Adult; D000368:Aged; D016572:Cyclosporine / Q000097:blood / Q000494:pharmacology*; D006684:HLA-DR Antigens / Q000032:analysis* / Q000235:genetics; D006239:Haplotypes; D006801:Humans; D016030:Kidney Transplantation; D008875:Middle Aged; D010641:Phenotype
chemical_list: D006684:HLA-DR Antigens; D016572:Cyclosporine